SEGMENT REPORTING (Tables)

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Schedule of certain information of these segments

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Revenues
Surgical products	$	14,246		$	15,280		$	45,662		$	45,142
Brachytherapy seed		5,841			6,053			18,476			18,284
Intersegment eliminations		(171	)		(271	)		(683	)		(575	)
	$	19,916		$	21,062		$	63,455		$	62,851
Earnings from operations
Surgical products	$	243		$	780		$	1,030		$	1,087
Brachytherapy seed		906			1,243			3,033			3,838
Intersegment eliminations		11			15			(12	)		2
	$	1,160		$	2,038		$	4,051		$	4,927
Capital expenditures, excluding asset acquisition
Surgical products	$	341		$	319		$	1,024		$	1,446
Brachytherapy seed		61			60			360			237
	$	402		$	379		$	1,384		$	1,683
Depreciation and amortization
Surgical products	$	1,232		$	973		$	3,675		$	3,407
Brachytherapy seed		541			839			2,218			1,997
	$	1,773		$	1,812		$	5,893		$	5,404

Schedule of supplemental information related to significant assets

	September 30, 2012			December 31, 2011
Identifiable assets
Surgical products	$	72,400		$	72,475
Brachytherapy seed		58,877			60,791
Corporate investment in subsidiaries		111,439			111,439
Intersegment eliminations		(136,818	)		(128,887	)
	$	105,898		$	115,818
Intangible assets
Surgical products	$	7,329		$	9,404
Brachytherapy seed		4,553			55
	$	11,882		$	9,459

Schedule of information regarding revenue by geographic regions

	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Product sales
United States	$	16,545	$	17,928	$	53,369	$	53,779
Europe		2,073		1,894		5,867		6,078
Other foreign countries		668		678		2,342		1,349
		19,286		20,500		61,578		61,206
License and fee income
United States		277		225		782		644
Canada		353		337		1,095		1,001
		630		562		1,877		1,645
	$	19,916	$	21,062	$	63,455	$	62,851